Invivoscribe, Inc.
Invivoscribe is a comprehensive partner for CDx development. For over 20 years, we have developed globally standardized molecular assays for hematologic malignancies in our FDA-registered, ISO 13485 certified facility. We offer CE-IVD and RUO-NGS assays and bioinformatics for B- & T-cell clonality, with US validations underway. Additionally, our reagents can be used to study MRD and monitor immunotherapy. Our network of ISO 15189 compliant labs in the US, Europe, and Asia provide clinical and research services to identify and track actionable somatic mutations throughout the course of disease.